Clinical Trial Update: A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TQB2858 injections combined with anlotinib hydrochloride in recurrent or metastatic advanced endometrial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• TQB2858

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Endometrial Carcinoma | Phase 2 | Status: UNKNOWN